CA3235971A1 - Methods and materials for expanding tumor infiltrating gamma-delta t cells - Google Patents
Methods and materials for expanding tumor infiltrating gamma-delta t cells Download PDFInfo
- Publication number
- CA3235971A1 CA3235971A1 CA3235971A CA3235971A CA3235971A1 CA 3235971 A1 CA3235971 A1 CA 3235971A1 CA 3235971 A CA3235971 A CA 3235971A CA 3235971 A CA3235971 A CA 3235971A CA 3235971 A1 CA3235971 A1 CA 3235971A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- cell population
- percent
- tcr
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163257805P | 2021-10-20 | 2021-10-20 | |
| US63/257,805 | 2021-10-20 | ||
| PCT/US2022/046745 WO2023069322A1 (en) | 2021-10-20 | 2022-10-14 | Methods and materials for expanding tumor infiltrating gamma-delta t cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3235971A1 true CA3235971A1 (en) | 2023-04-27 |
Family
ID=85980818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3235971A Pending CA3235971A1 (en) | 2021-10-20 | 2022-10-14 | Methods and materials for expanding tumor infiltrating gamma-delta t cells |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230117388A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4419118A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024539088A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3235971A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023069322A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025082502A1 (en) * | 2023-10-18 | 2025-04-24 | Nanjing Legend Biotech Co., Ltd. | Pan t cells and methods of manufacturing of the same |
| ES3034332B2 (es) * | 2025-05-21 | 2026-05-08 | Univ Madrid Complutense | Método de expansión selectiva in vitro y adquisición de fenotipo residente en tejido decélulas T Yo Vo1+ derivadas de sangre periférica |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2336302T3 (es) * | 2000-04-03 | 2010-04-12 | Therapure Biopharma Inc. | Produccion de celulas ttcr gamma delta. |
| US9907820B2 (en) * | 2013-10-25 | 2018-03-06 | Board Of Regents, The University Of Texas System | Polyclonal gamma delta T cells for immunotherapy |
| GB201506423D0 (en) * | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| RU2756247C2 (ru) * | 2014-11-17 | 2021-09-28 | Эдисет Био, Инк. | Генетически модифицированные гамма дельта т-клетки |
| CN118421557A (zh) * | 2016-05-12 | 2024-08-02 | 阿迪塞特治疗公司 | 选择性扩增γδT细胞群的方法及其组合物 |
| GB201707048D0 (en) * | 2017-05-03 | 2017-06-14 | King S College London | Expansion of gamma delta cells, compositions, and methods of use thereof |
| WO2018229163A1 (en) * | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| CA3082818A1 (en) * | 2017-11-15 | 2019-05-23 | Adicet Bio Inc. | Methods for selective expansion of .delta.3 .gamma..delta. t-cell populations and compositions thereof |
| EP3927353A4 (en) * | 2019-02-24 | 2022-11-23 | Gamida-Cell Ltd. | METHOD OF ECOTAXY AND RETENTION OF GAMMADELTA T LYMPHOCYTES, OPTIONALLY WITH NATURAL KILLER CELLS, ALLOWING THE GENERATION OF CELLULAR COMPOSITIONS FOR USE IN THERAPY |
| CA3148588A1 (en) * | 2019-08-16 | 2021-02-25 | GammaDelta Therapeutics Limited | Ex vivo gamma delta t cell populations |
-
2022
- 2022-10-14 WO PCT/US2022/046745 patent/WO2023069322A1/en not_active Ceased
- 2022-10-14 JP JP2024523401A patent/JP2024539088A/ja active Pending
- 2022-10-14 US US17/966,444 patent/US20230117388A1/en active Pending
- 2022-10-14 EP EP22884294.4A patent/EP4419118A4/en active Pending
- 2022-10-14 CA CA3235971A patent/CA3235971A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230117388A1 (en) | 2023-04-20 |
| JP2024539088A (ja) | 2024-10-28 |
| WO2023069322A9 (en) | 2023-08-10 |
| EP4419118A1 (en) | 2024-08-28 |
| EP4419118A4 (en) | 2025-04-30 |
| WO2023069322A1 (en) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7860161B2 (ja) | 非造血組織常在性γδ T細胞の増幅および該細胞の使用 | |
| US11905529B2 (en) | Method of enhancing persistence of adoptively infused T cells | |
| Vacca et al. | Human natural killer cells and other innate lymphoid cells in cancer: Friends or foes? | |
| JP7373543B2 (ja) | 2型自然リンパ球細胞、インターロイキン33、及び/またはインターフェロン誘導性タンパク質44による癌免疫の調節 | |
| EP3200818B1 (en) | Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation | |
| ES2980469T3 (es) | Métodos para producir linfocitos T autólogos útiles para tratar cánceres y composiciones de los mismos | |
| CN103635573A (zh) | 包含γδT细胞的淋巴细胞系、其组合物及生产方法 | |
| JP2023540361A (ja) | 養子細胞療法に対する応答に関連するt細胞表現型 | |
| US20230138309A1 (en) | Methods of isolating t-cells and t-cell receptors from tumor by single-cell analysis for immunotherapy | |
| US20230117388A1 (en) | Methods and materials for expanding tumor infiltrating gamma-delta t cells | |
| de Mey et al. | An mRNA mix redirects dendritic cells towards an antiviral program, inducing anticancer cytotoxic stem cell and central memory CD8+ T cells | |
| US20210290672A1 (en) | Regulation of tumor-associated t cells | |
| JP2023516538A (ja) | Ucart細胞を精製する方法及び応用 | |
| Naizir et al. | TOX drives CD4+ TH1 effector function, antitumor immunity and autoimmune pathology | |
| US20250333699A1 (en) | Method for preparation of cytotoxic t lymphocytes with broad tumour-specific reactivity and characteristics of early differentiation cells | |
| CN114599784A (zh) | 具有cd45ra+和ccr7+的细胞表面标志物的t细胞的制备方法 | |
| US20240150711A1 (en) | Personalized redirection and reprogramming of t cells for precise targeting of tumors | |
| US20250041344A1 (en) | Gene editing methods for modulating expression of id-3, an inhibitor of dna-binding transcription factors, thereby affecting t-cell function | |
| RU2808595C1 (ru) | Способ получения культуры лимфоцитов, обогащенных опухоль-специфичными клонами т-лимфоцитов, и клеточные культуры, полученные с использованием указанного способа | |
| Prokhnevska | CD8 T cell activation in cancer is comprised of two distinct phases | |
| EP4538366A1 (en) | Enhancing lineage stability of therapeutic regulatory t cell products | |
| Han | Profiling Durable Anti-Tumor Memory T Cell Responses in Long-Term Melanoma Survivors | |
| Venkatesh | B Cell Leukemia Elicits a Suppressive Tr1-CD4+ T Cell Response That Can Be Reprogrammed With PDL1-Blockade | |
| JP7524210B2 (ja) | Cd28 t細胞培養物、組成、およびその使用方法 | |
| Yao | Reshape of CAR-T cells by overexpression of TCF-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241014 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241014 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241014 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250819 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250819 |